PCPriscila Cilene Leon Bueno de Camargo

Priscila Cilene Leon Bueno de Camargo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Priscila Cilene Leon Bueno de Camargo has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Accessing the Impacts of the Calculated Panel Reactive Antibody Value on a Lung Transplant Waitlist: A Latin American Experience

    by Samuel Lucas dos Santos, Flavio Pola dos Reis, Luis Gustavo Abdalla, Lucas Matos Fernandes, Elissa Ayumi Okuno, Priscila Cilene Leon Bueno Camargo, Rafael Medeiros Carraro, Silvia Vidal Campos, Ricardo Henrique Oliveira Braga Teixeira, Paulo Manuel Pêgo-Fernandes

    Backgorund\Objectives: Lung transplantation is the definitive treatment for select patients with end-stage pulmonary diseases. However, immunologic sensitization, as measured by calculated panel-reactive antibody (cPRA), poses significant challenges to transplant access and outcomes. This study aimed to evaluate the impact of cPRA on lung transplantation waitlist dynamics in a single-center cohort in Brazil, focusing on its association with waitlist mortality, delisting, and transplantation. Methods: A retrospective cohort study was conducted including all lung transplant candidates listed in our institution between January 2012 and December 2022. Candidates were stratified by cPRA values at listing into five groups: 0%, 0.1–25%, 25.1–50%, 50.1–75%, and 75.1–100%. Primary outcomes included lung transplantation, with secondary outcomes of waitlist mortality and delisting due to clinical deterioration. Statistical comparisons were performed, as appropriate. Results: Of the 411 candidates evaluated, 327 met the inclusion criteria. Among them, 100 (30.6%) were sensitized (cPRA > 0%), with increasing cPRA values correlating with longer median waitlist times (p < 0.01). Although transplantation rates were not statistically different across the cPRA strata (p = 0.277), the group with a cPRA > 75% had the lowest transplant rate (37.5%). Waitlist mortality was significantly higher in candidates with a cPRA > 50% (p = 0.047), whereas delisting rates did not differ across groups (p = 0.722). Conclusions: Elevated cPRA is associated with prolonged waitlist time and increased mortality, reflecting both immunologic and logistical barriers to lung transplantation. These findings support the need for incorporating cPRA into allocation policies and adopting targeted strategies, such as desensitization protocols, to improve equity in transplant access for sensitized patients, particularly in genetically diverse populations. Further multicenter studies are warranted to validate these results and inform policy development.


  • Open Access

    P14.01: Cryobiopsy in the Diagnosis of Lung Allograft Rejection: Brazilian Case Series

    by Carlos E F Belon, Elissa A Okuno, Silvia V Campos, Ascedio J Rodrigues, Evelisse Lima, Paulo R Scordamaglio, Priscila C L B Camargo, Ricardo H O B Teixeira, Rafael M Carraro, Andre N Costa, et al.

  • Open Access

    Brazilian initial experience with lung transplantation due to irreversible lung fibrosis post-COVID-19 in a national reference center: a cohort study

    by Flavio Pola dos Reis, Lucas Matos Fernandes, Luis Gustavo Abdalla, Silvia Vidal Campos, Priscila Cilene Leon Bueno de Camargo, Samuel Lucas dos Santos, Ivana Teixeira de Aguiar, Juliana Patricia Pires, Andre Nathan Costa, Rafael Medeiros Carraro, et al.

    BACKGROUND: Lung transplantation (LTx) has been discussed as an option for treating irreversible lung fibrosis post-coronavirus disease 2019 (COVID-19), in selected cases. OBJECTIVES: To report on the initial experience and management of end-stage lung disease due to COVID-19 at a national center reference in Brazil. DESIGN AND SETTING: Cohort study conducted at a national reference center for lung transplantation. METHODS: Medical charts were reviewed regarding patients'demographics and pre-COVID-19 characteristics, post-LTx due to COVID-19. RESULTS: Between March 2020 and September 2021, there were 33 cases of LTx. During this period, we evaluated 11 cases of severe COVID-19-related acute respiratory distress syndrome (ARDS) that were potentially candidates for LTx. Among these, LTx was only indicated for three patients ( 9.1%). All of these patients were on venovenous extracorporeal membrane oxygenation ( ECMO), and the procedure that they underwent was central venoarterial ECMO. All three patients were still alive after the first 30 postoperative days. However, patient #1 and patient #2 subsequently died due to fungal sepsis on the 47th and 52nd postoperative days, respectively. Patient #3 was discharged on the 30th postoperative day. CONCLUSIONS: LTx is feasible among these complex patients. Survival over the first 30 days was 100%, and this favors surgical feasibility. Nonetheless, these were critically ill patients.


  • Open Access

    Extracorporeal Membrane Oxygenation and Lung Transplantation: Initial Experience at a Single Brazilian Center

    by Flávio Pola-Dos-Reis, Marcos Naoyuki Samano, Luis Gustavo Abdalla, Guilherme Vieira Soares de Carvalho, Lucas Matos Fernandes, Oswaldo Gomes-Júnior, Rafael Medeiros Carraro, Priscila Cilene Leon Bueno de Camargo, Ricardo Henrique Oliveira Braga Teixeira, José Eduardo Afonso-Júnior, et al.

    To report initial experience from the use of extracorporeal membrane oxygenation (ECMO) in patients who received lung transplantation. Retrospective study of a single tertiary center in the Brazilian state of São Paulo, a national reference in lung transplantation, based on the prospective collection of data from electronic medical records. The period analyzed extended from January 2009 (beginning of the program) until December 2018. A total of 75 lung transplants were performed, with ECMO used in 8 (10.7%) cases. Of the patients, 4 (50%) were female. The mean age was 46.4±14.3 years. The causes of the end-stage lung disease that led to transplantation were pulmonary arterial hypertension in 3 (37.5%) patients, bronchiectasis in 2 (25%) patients, pulmonary fibrosis in 2 (25%) patients, and pulmonary emphysema in 1 (12.5%) patient. In our series, 7 (87.5%) cases were sequential bilateral transplantations. Prioritization was necessary in 4 (50%) patients, and in 1 patient, ECMO was used as a bridge to transplantation. The ECMO route was central in 4 (50%), peripheral venovenous in 2 (25%) and peripheral venoarterial in 2 (25%) patients. The mean length of the intensive care unit (ICU) stay was 14±7.5 days and of the hospital stay was 34.1±34.2 days. The mean ECMO duration was 9.3±6.6 days with a 50% decannulation rate. Three patients were discharged (37.5%). Lung transplantation requires complex treatment, and ECMO has allowed extending the indications for transplantation and provided adjuvant support in the clinical management of these patients.


  • Open Access

    Lung transplantation: overall approach regarding its major aspects

    by Priscila Cilene León Bueno de Camargo, Ricardo Henrique de Oliveira Braga Teixeira, Rafael Medeiros Carraro, Silvia Vidal Campos, José Eduardo Afonso Junior, André Nathan Costa, Lucas Matos Fernandes, Luis Gustavo Abdalla, Marcos Naoyuki Samano, Paulo Manuel Pêgo-Fernandes

    Lung transplantation is a well-established treatment for patients with advanced lung disease. The evaluation of a candidate for transplantation is a complex task and involves a multidisciplinary team that follows the patient beyond the postoperative period. Currently, the mean time on the waiting list for lung transplantation in the state of São Paulo, Brazil, is approximately 18 months. For Brazil as a whole, data from the Brazilian Organ Transplant Association show that, in 2014, there were 67 lung transplants and 204 patients on the waiting list for lung transplantation. Lung transplantation is most often indicated in cases of COPD, cystic fibrosis, interstitial lung disease, non-cystic fibrosis bronchiectasis, and pulmonary hypertension. This comprehensive review aimed to address the major aspects of lung transplantation: indications, contraindications, evaluation of transplant candidates, evaluation of donor candidates, management of transplant recipients, and major complications. To that end, we based our research on the International Society for Heart and Lung Transplantation guidelines and on the protocols used by our Lung Transplant Group in the city of São Paulo, Brazil.


  • Open Access

    Psychological criteria for contraindication in lung transplant candidates: a five-year study

    by Elaine Marques Hojaij, Bellkiss Wilma Romano, André Nathan Costa, Jose Eduardo Afonso Junior, Priscila Cilene Leon Bueno de Camargo, Rafael Medeiros Carraro, Silvia Vidal Campos, Marcos Naoyuki Samano, Ricardo Henrique de Oliveira Braga Teixeira

    Lung transplantation presents a wide range of challenges for multidisciplinary teams that manage the care of the recipients. Transplant teams should perform a thorough evaluation of transplant candidates, in order to ensure the best possible post-transplant outcomes. That is especially true for the psychologist, because psychological issues can arise at any point during the perioperative period. The objective of our study was to evaluate the psychological causes of contraindication to waiting list inclusion in a referral program for lung transplantation. We retrospectively analyzed data on psychological issues presented by lung transplant candidates, in order to understand these matters in our population and to reflect upon ways to improve the selection process.


  • Open Access

    Cytokine levels in pleural fluid as markers of acute rejection after lung transplantation

    by Priscila Cilene León Bueno de Camargo, José Eduardo Afonso Jr, Marcos Naoyuki Samano, Milena Marques Pagliarelli Acencio, Leila Antonangelo, Ricardo Henrique de Oliveira Braga Teixeira

    Our objective was to determine the levels of lactate dehydrogenase, IL-6, IL-8, and VEGF, as well as the total and differential cell counts, in the pleural fluid of lung transplant recipients, correlating those levels with the occurrence and severity of rejection. We analyzed pleural fluid samples collected from 18 patients at various time points (up to postoperative day 4). The levels of IL-6, IL-8, and VEGF tended to elevate in parallel with increases in the severity of rejection. Our results suggest that these levels are markers of acute graft rejection in lung transplant recipients.